Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
Martin Reck, Shun Lu, Kenneth J O'Byrne...
https://pubmed.ncbi.nlm.nih.gov/41388832/Actively Recruiting
Led by Pfizer · Updated on 2026-09-25
714
Participants Needed
389
Research Sites
25 weeks
Total Duration
Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.
CONDITIONS
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SV + Pembrolizumab | Pembrolizumab alone |
|---|---|---|
| What it is | A phase 3 randomized, open‑label study adding Sigvotatug Vedotin (an integrin β‑6‑targeted antibody‑drug conjugate) to pembrolizumab as first‑line treatment in advanced NSCLC with PD‑L1 ≥50% | Pembrolizumab monotherapy is used in the study as the active comparator and reflects current standard first‑line treatment for PD‑L1 ≥50% NSCLC |
| Role in the trial | Investigational combination being evaluated for efficacy and safety | Active comparator arm representing standard‑of‑care pembrolizumab |
| Primary use | To assess whether adding Sigvotatug Vedotin can improve outcomes compared to standard pembrolizumab monotherapy | First‑line monotherapy for advanced NSCLC with PD‑L1 ≥50%, serving as standard benchmark |
| How it is given or performed | Sigvotatug Vedotin administered intravenously every two weeks plus pembrolizumab IV every six weeks in 42‑day cycles | Pembrolizumab monotherapy administered intravenously every six weeks in 42‑day cycles |
| Evidence status | Evidence is emerging; early phase data showed promising antitumor activity and manageable safety, but phase 3 results are pending | Strong evidence supports pembrolizumab monotherapy as effective first‑line treatment in PD‑L1 ≥50% NSCLC |
| Important risks | Safety profile is being evaluated; early studies suggest manageable toxicity but full safety not yet established | Known risk profile includes immune‑related adverse events; safety established from clinical trials and real‑world data |
| Important limitations | Efficacy and safety are not yet proven; results from this ongoing phase 3 study are awaited | Effectiveness may vary in broader real‑world populations outside trial eligibility |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are evaluated for eligibility based on their medical history, cancer stage, PD-L1 levels, and overall health to ensure they meet the study criteria.
1 visit (in-person)
Duration - Up to 2 years
Participants receive pembrolizumab every 6 weeks by intravenous infusion. Half also receive Sigvotatug Vedotin every 2 weeks by intravenous infusion. Treatment continues until disease progression or up to about two years.
Clinic visits every 2 to 6 weeks
Duration - Up to 2 years
Participants are regularly monitored to assess overall survival, disease progression, and response to treatment through clinical assessments and imaging.
Regular follow-up visits for up to 2 years
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Martin Reck, Shun Lu, Kenneth J O'Byrne...
https://pubmed.ncbi.nlm.nih.gov/41388832/Pfizer
Lead Sponsor